ACADIA Pharmaceuticals Inc. (ACAD) News
Track canonical SquawkNews coverage tagged to ACAD, ACADIA Pharmaceuticals Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 25 indexed stories across 13 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
ACADIA Pharmaceuticals - On Aug 24, Court Preliminarily Approves Settlement Of Kanner Et Al. V. Biggar Et Al. Derivative Action - SEC Filing
Acadia Pharmaceuticals Inc. NASDAQ:ACAD
REGULATION | Sep 11, 2026, 09:25 PM UTC
L
Acadia Pharmaceuticals reaches preliminary settlement in derivative suit; $1.5M fees, four-year governance reforms
Acadia Pharmaceuticals reached a preliminary court-approved settlement of a stockholder derivative action requiring adoption of corporate governance reforms and a $1,500,000 fee for stockholders' counsel.Key Highlights:O
REGULATION | Sep 11, 2026, 09:24 PM UTC
L
ACAD: Record growth and profitability achieved, fueled by quality, expansion, and acquisitions
ACAD: Record growth and profitability achieved, fueled by quality, expansion, and acquisitions
EQUITY | Aug 31, 2026, 08:20 AM UTC
L
Academedia Q4 net sales rise 10.6% to SEK 5,658m
Academedia reported Q4 net sales increasing 10.6% to SEK 5,658 million.
EQUITY | Aug 31, 2026, 05:03 AM UTC
L
ACAD: Sales and profit rose on strong international growth and acquisitions, with margins improving
ACAD: Sales and profit rose on strong international growth and acquisitions, with margins improving
EQUITY | Aug 31, 2026, 05:01 AM UTC
L
AcadeMedia interim report for July 2025–June 2026
AcadeMedia published its interim report for the period July 2025 through June 2026.
EQUITY | Aug 31, 2026, 05:00 AM UTC
M
European Commission approves ACAD's DAYBU for Rett syndrome
ACAD says the European Commission approves DAYBU (trofinetide) as the first and only treatment for neurobehavioral symptoms of Rett syndrome in the European Union.
REGULATION | Aug 24, 2026, 01:32 PM UTC
L
ACAD PT Raised to $41 by Needham
Needham raises ACAD price target to $41 from $38
EQUITY | Aug 12, 2026, 10:47 AM UTC
L
ACADIA Pharmaceuticals Raises FY2026 Sales Guidance from $1.220B-$1.280B to $1.240B-$1.300B vs $1.242B Est
ACADIA Pharmaceuticals (NASDAQ: ACAD ) raises FY2026 sales outlook from $1.220 billion-$1.280 billion to $1.240 billion-$1.300 billion vs $1.242 billion estimate.
EARNINGS | Aug 04, 2026, 08:33 PM UTC
H
US Stocks: Earnings After Market
Multiple US companies report earnings
EARNINGS | Aug 04, 2026, 09:07 AM UTC
H
US Stocks: Earnings After Market
Multiple US companies report earnings
EARNINGS | Aug 03, 2026, 08:49 PM UTC
L
ACAD Affirm Outperform rating and increase PT to $36 @ BMO
ACAD Affirm Outperform rating and increase PT to $36 @ BMO
EQUITY | Jul 21, 2026, 12:46 PM UTC
L
ACAD Remlifanserin Deep Dive: Previewing ADP, Where Stifel Are Skeptical But Acknowledge an Upside Biased Stock Risk/Reward @ Stifel
ACAD Remlifanserin Deep Dive: Previewing ADP, Where Stifel Are Skeptical But Acknowledge an Upside Biased Stock Risk/Reward @ Stifel
EQUITY | Jul 21, 2026, 11:27 AM UTC
L
ACAD Acadia Pharmaceuticals receives FDA fast track designation for remlifanserin in Alzheimer's Disease psychosis Acadia Pharmaceuticals
ACAD Acadia Pharmaceuticals receives FDA fast track designation for remlifanserin in Alzheimer's Disease psychosis Acadia Pharmaceuticals - completes radiant phase 2 enrollment; topline results expected September-october
REGULATION | Jul 20, 2026, 01:05 PM UTC
H
Acadia Pharmaceuticals price target raised to $36 from $29 at RBC Capital
RBC Capital analyst Brian Abrahams raised the firm's price target on Acadia Pharmaceuticals to $36 from $29 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotec
RATES | Jul 07, 2026, 11:16 AM UTC
L
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
Experienced global HR leader joins Acadia to advance people strat
EQUITY | Jul 06, 2026, 01:04 PM UTC
L
B of A Securities Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $30
B of A Securities analyst Tazeen Ahmad maintains ACADIA Pharmaceuticals (NASDAQ: ACAD ) with a Buy and raises the price target from $29 to $30.
EQUITY | Jun 30, 2026, 05:36 PM UTC
M
Canaccord Genuity Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $36
Canaccord Genuity analyst Sumant Kulkarni maintains ACADIA Pharmaceuticals (NASDAQ: ACAD ) with a Buy and raises the price target from $32 to $36.
EQUITY | Jun 29, 2026, 01:36 PM UTC
H
Oil Falls 4%
Crude oil prices fall 4% to $69.05, while US consumer sentiment rises to 49.5 in June
COMMODITIES | Jun 26, 2026, 04:17 PM UTC
M
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Friday. Shares of Apogee Enterprises In c (NASDAQ: APOG ) rose sharply after the company reported better-than-expected first-quarter financ
EARNINGS | Jun 26, 2026, 01:39 PM UTC
H
ACAD +17% on EU Approval
ACAD rises 17% premarket after DAYBU receives European Union approval recommendation from CHMP
EQUITY | Jun 26, 2026, 01:08 PM UTC
H
US Premarket Movers
Select US stocks are moving premarket due to various announcements and earnings reports
EQUITY | Jun 26, 2026, 12:37 PM UTC
M
12 Health Care Stocks Move
Twelve health care stocks are moving in Friday's pre-market session, with gainers including Quantum Cyber and INVO Fertility, and losers including Creative Medical Tech and Omeros
EQUITY | Jun 26, 2026, 12:05 PM UTC
L
ACAD DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
ACAD DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
EQUITY | Jun 26, 2026, 10:53 AM UTC